CC 5013

Phase 3Small molecule

Bristol-Myers Squibb

CC 5013 is one of 239 small molecule programs targeting Primary Systemic Amyloidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

238

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Systemic AmyloidosisActive, not recruiting

Lung CancerActive, not recruiting

MyelofibrosisActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Primary Systemic AmyloidosisPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

MyelofibrosisPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

CC 5013

Bristol-Myers Squibb

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

Lenvima

Eisai

Preclinical

6 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma6 trials

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1·NCT00153933·58 enrolled

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00065351·222 enrolled

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00091624·77 enrolled

Show 3 more trials

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00622336·330 enrolled

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00051116·100 enrolled

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00056160·353 enrolled

Melanoma3 trials

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00055562·274 enrolled

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00057616·274 enrolled

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00179608·28 enrolled

Primary Peritoneal Carcinoma2 trials

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00179725·60 enrolled

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00179712·60 enrolled

Lenalidomide1 trial

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00179751·50 enrolled

Myelodysplastic Syndrome1 trial

Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00044382·25 enrolled

6 more indications

Primary Systemic Amyloidosis1 trial

Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis

Completed·MMayo Clinic·Phase 2·NCT00166413·38 enrolled

Myelofibrosis1 trial

A Phase II Study of CC-5013 in Myelofibrosis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00087672·41 enrolled

Non-Small Cell Lung Cancer1 trial

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00179699·40 enrolled

Myelodysplastic Syndromes1 trial

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00064974·215 enrolled

Crohn's Disease1 trial

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00446433·90 enrolled

Lung Cancer1 trial

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00179686·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for CC 5013. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC 5013 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC 5013. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

CC 5013

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma6 trials

Melanoma3 trials

Primary Peritoneal Carcinoma2 trials

Lenalidomide1 trial

Myelodysplastic Syndrome1 trial

Primary Systemic Amyloidosis1 trial

Myelofibrosis1 trial

Non-Small Cell Lung Cancer1 trial

Myelodysplastic Syndromes1 trial

Crohn's Disease1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News